Abstracts tagged "SLE and remission"

Abstract Number: 1840 • 2017 ACR/ARHP Annual Meeting
Comparison of Different Definitions of Remission in Systemic Lupus Erythematosus (SLE)– a Study Based on the BLISS-76 Clinical Trial
Sharzad Emamikia¹, Cidem Gentline¹, Elizabeth V. Arkema², Laurent Arnaud³, Katerina Chatzidionysiou^1,4 and Ronald F van Vollenhoven^5,6, ¹Department of Medicine, (ClinTRID), Karolinska Institute, Stockholm, Sweden, ²Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology, Université de Strasbourg, Strasbourg, France, ⁴On behalf of the SRQ/ARTIS registry, Stockholm, Sweden, ⁵Department of Medicine, (ClinTRID), Karolinska Institute, Solna, Sweden, ⁶AMC, F4-214, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands
Background/Purpose: Remission in SLE is a desirable target, however there is no gold standard for the definition of remission. An international task force agreed on…
Abstract Number: 986 • 2015 ACR/ARHP Annual Meeting
Application of New EULAR Definitions of Remission in SLE: Durable 1-Year Remission Is Rare
Theresa Fischer¹, Laurence S Magder² and Michelle Petri³, ¹Charité-Universitätsmedizin, Berlin, Germany, ²University of Maryland School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University Hospital, Baltimore, MD
Background/Purpose: Developing definition(s) of remission in SLE is one of the primary recommendations on the research agenda of the treat-to-taget international task force. Definitions of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].